Reduced combined radiotherapy and chemotherapy for Hodgkin's disease--risk-adapted treatment approach.
Herold
M
M
Klinik für Innere Medizin, Medizinische Akademie Erfurt, GDR.
Anger
G
G
Keinert
K
K
Höche
D
D
Kästner
R
R
Wutke
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D012307:Risk Factors; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D009588:Nitrogen Mustard Compounds; D001761:Bleomycin; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D008130:Lomustine; D011241:Prednisone; D003630:Daunorubicin